HomeMarkets overviewSharesAytu BioScience, Inc.

Trade Aytu BioScience, Inc. - AYTU CFD

Market is not available at the momentMarket information is presented
as of 2026-05-29 19:47:26
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.104
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.021485 %
(-$1.07)

Trade size with leverage ~ $5,000.00

Money from leverage ~$4,000.00


-0.02149%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000738 %
(-$0.04)

Trade size with leverage ~ $5,000.00

Money from leverage ~$4,000.00


-0.00074%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin20.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close2.183
Open2.163
1-Year Change13.6%
Day's Range2.143 - 2.293

Trade Aytu BioScience, Inc. - AYTU CFD

About Aytu Biopharma Inc

Aytu Biopharma, Inc., formerly Aytu BioScience, Inc., is a specialty pharmaceutical company. The Company markets a portfolio of prescription products addressing primary care and pediatric markets. The Company's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. It markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The Company's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.

Financial summary

BRIEF: For the six months ended 31 December 2021, Aytu Biopharma Inc revenues increased 57% to $45M. Net loss increased from $13.8M to $39.4M. Revenues reflect United States segment increase of 69% to $43.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$1.07 to -$1.53.

Equity composition

Common Stock no Par, 11/11, 30M auth., 4,774,568 issd. Insiders own 66.98%. 06/15, 1-for-12.174, Reverse Stock Split.

Latest shares articles

Round illuminated Campari sign mounted on a red wall with white Campari Milano branding
Davide Campari-Milano stock forecast: Q1 2026 earnings
Davide Campari-Milano is an Italian spirits group listed in Milan. Its Q1 2026 update showed 2.9% organic sales growth, below analyst estimates. Explore third-party CPR price targets and technical analysis. Past performance is not a reliable indicator of future results.
13:18, 21 May 2026
Deutz logo
DEUTZ stock forecast: Q1 2026 results
DEUTZ AG’s Q1 2026 results, released 7 May, shows new orders up 41.2% and revenue up 8.4%, as investors assess its new five-division structure and the impact of US import duties on customer pricing. Explore third-party DEZ predictions. Past performance is not a reliable indicator of future results.
13:02, 20 May 2026
Monte dei Paschi di Siena bank logo displayed on a wall sign
BCA MPS stock forecast: Mediobanca merger integration
Banca Monte dei Paschi di Siena reported Q1 2026 net profit of €521m, while Mediobanca integration continued after its completed takeover. Explore third-party BMPS price targets and technical analysis. Past performance is not a reliable indicator of future results.
10:43, 19 May 2026
Close-up of a smartphone displaying the UniCredit logo against a blurred red background.
UniCredit stock forecast: Q1 2026 earnings, Commerzbank bid
UniCredit is an Italian banking group listed in Milan. Its 2026 outlook is linked to record Q1 profit and its €35bn all-share bid for Commerzbank. Explore third-party UCG price targets and technical analysis. Past performance is not a reliable indicator of future results.
09:33, 19 May 2026

User feedback and ratings

Read the feedback from our clients1, whatever their experience level.
2025-07-01
P**** R******

I'm learning the basics of stock investing. This platform is clear and pretty good. I've been using it for over 6 months.

2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-22
J*** A.

The app is built to make options and figures easy to understand, great for beginners and intermediate traders. Demo accounts are simple to set up. 100:1 leverage is available.

2025-06-22
D******

Deposits and withdrawals work without issues. Very low spreads. No noticeable fees. Easy to follow.

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-16
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Three steps to get started

1. Create your account (subject to eligibility)2. Deposit on your terms3. Trade when you’re ready